Genocea Biosciences, Inc. – Nasdaq: GNCA
Genocea Biosciences Inc. reported positive results in a Phase 2b clinical trial. Shares (Nasdaq: GNCa) are up over 13% on the news.
Chip Clark, president and chief executive officer of Genocea stated “We are very pleased to have demonstrated such a powerful impact on genital herpes clinical disease in this trial, supporting the groundbreaking potential of GEN-003 to be the first-ever therapeutic vaccine for a chronic infection and the first advance in the treatment of genital herpes in more than 20 years…”
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs.
Five firms follow Gencocea Biosciences Inc. Four rate GNCA as a “Strong Buy” and one rates GNCA a “Buy”. Their consensus pricet target is $15. Genocea Bioscinces reported sales of $700,000 in 2015. This represented a drop from their 2012 reported sales of $2 million. EPS for GNCA have a similar history. Never achieving positive EPS, GNCA had its worst reporting year in 2014 when they lost $2.27 EPS. In 2015 GNCA improved to a loss of $$1,74 EPS.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 8:50 AM EST||$5.15|
|Market Cap||$130.4 million|
|Shares Outstanding||28.74 million|
|Share Float||24.8 million|
|Short Interest Ratio||16.56|